Company intelligence / Profile preview
Zydus Lifesciences
- Ownership
- Private
- Employees
- ~24000
- Development stage
- Other
Overview
Zydus Lifesciences is a large, commercial-stage pharmaceutical and biotech company with a global footprint across generics, biosimilars, vaccines, and novel new chemical entities. It was the first Indian company to launch a patented NCE (Lipaglyn/saroglitazar) and an adalimumab biosimilar (Exemptia). Dozens of generics are approved in the US, along with both complex generics and biologics. They have a strong ongoing clinical pipeline in NCE, biosimilars, and vaccines, with multiple programs in commercial or late-phase development.[2][4][7][10]
- Therapeutic areas
- ImmunologyEndocrinologyRheumatologyInfectious DiseasesGastroenterologyPulmonologyCardiovascularNeurology
- Modalities
- Small moleculeMonoclonal antibodyBiosimilarVaccineProteinRecombinant protein
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Zydus Lifesciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zydus Lifesciences.